Research Article

A Human Brain Microphysiological System Derived from Induced Pluripotent Stem Cells to Study Neurological Diseases and Toxicity

David Pamies¹, Paula Barreras²,³, Katharina Block¹, Georgia Makri²,⁴, Anupama Kumar²,³, Daphne Wiersma¹, Lena Smirnova¹, Ce Zhang²,⁴, Joseph Bressler⁶, Kimberly M. Christian²,⁴, Georgina Harris¹, Guo-li Ming²,⁴,⁶, Cindy J. Berlinicke⁷, Kelly Kyro⁸, Hongjun Song²,⁴,⁶, Carlos A. Pardo², Thomas Hartung¹,⁹ and Helena T. Hogberg¹

¹Center for Alternatives to Animal Testing, ²Department of Neurology, ³Division of Neuroimmunology, ⁴Institute for Cell Engineering, ⁵Hugo Moser Institute at the Kennedy Krieger, ⁶The Solomon Snyder Department of Neuroscience, ⁷Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA. ⁸US Army Edgewood Chemical Biological Center, Aberdeen Proving Ground, MD, USA ⁹University of Konstanz, Konstanz, Germany

Summary

Human in-vitro models of brain neurophysiology are needed to investigate molecular and cellular mechanisms associated with neurological disorders and neurotoxicity. We have developed a reproducible iPSC-derived human 3D brain microphysiological system (BMPS), comprised of differentiated mature neurons and glial cells (astrocytes and oligodendrocytes) that reproduce neuronal-glial interactions and connectivity. BMPS mature over eight weeks and show the critical elements of neuronal function: synaptogenesis and neuron-to-neuron (e.g. spontaneous electric field potentials) and neuronal-glial interactions (e.g. myelination), that mimic the microenvironment of the central nervous system, rarely seen in vitro so far. The BMPS shows 40% overall myelination after 8 weeks of differentiation. Myelin was observed by immunohistochemistry and confirmed by confocal microscopy 3D reconstruction and electron microscopy. These findings are of particular relevance since myelin is crucial for proper neuronal function and development. The ability to assess oligodendroglia function and mechanisms associated with myelination in this BMPS model provide an excellent tool for future studies of neurological disorders such as multiple sclerosis and other demyelinating diseases. Thus, the BMPS provides a suitable and reliable model to investigate neuron-neuroglia function in neurotoxicity or other pathogenic mechanisms.

Keywords: 3D culture, CNS, myelination, microphysiological system, brain.

1 Introduction

There is lack of mechanistic understandings of processes related to (developmental) neurotoxicity (Smirnova et al., 2014; Schmidt et al., 2016) and neurological disorders partly due to limited human representative models. Animal-based models have poor predictivity for human health (Hartung, 2013, 2008), and do not always mimic human pathology. More than 90% of all drugs fail clinical trials after extensive animal testing (Hartung, 2013) in part because animal studies do not reflect human physiology and inter-individual differences. Simple in vitro systems do not represent the complex physiology and organ function (Hartung, 2007), especially that of the brain. This illustrates a critical need for better models in drug development, the study of disease, bioengineering and toxicological testing.

Some attempts to generate more complex organotypic cultures or microphysiological systems (MPS) have resulted in physiological multicellular 3D co-culture models with the ability to simulate functional parts of the brain (Lancaster et al., 2013; Kadoshima et al., 2013). Furthermore, the discovery of induced pluripotent stem cells (iPSC) and protocols to differentiate them into various cell types has boosted the development of new human in vitro models (Takahashi et al., 2007). iPSC from healthy or patient donors (Nieweg et al., 2015; Raitano et al., 2015) used in MPS promise more human-representative models, such as brain organoids that have been able to recapitulate features of human cortical development (Lancaster et al., 2013; Kadoshima et al., 2013). These complex systems represent novel tools for the study of biological mechanisms in the CNS. Their application to drug screening and chemical testing, however, has limitations. Some require elaborate and complex protocols and have size differences between organoids, which leads to marked variations in number of cells and composition that may negatively impact reproducibility in cell differentiation. Moreover, necrosis in the center...
of the organoids can occur if they are larger than 400 nm. Most of these models have focused on the neuronal composition even though the in vivo brain also consists of several other cell types such as astrocytes and oligodendrocytes. We developed a novel in-vitro iPSC-derived human 3D brain microphysiological system (BMPS), which is comprised of mature neurons (glutamatergic, dopaminergic and GABAergic neurons) and glial cells (astrocytes and oligodendrocytes). Quantification of the different cell types exhibited high reproducibility between experiments. Moreover, the BMPS presents neuron and glial functions such as spontaneous electrical activity and axon myelination. Especially the high amount of myelination of axons in this BMPS (up to 40%) is significant, as only a few models have shown to recapitulate this process in vitro. Myelin pathology is a rather frequent condition in demyelinating and inflammatory disorders such as multiple sclerosis and post-infection diseases as well as other neurological diseases such as acute and post-traumatic brain injury, stroke and neurodegenerative disorders (Fumagalli et al., 2016; Tse and Herrup, 2016). Moreover, the myelination process can be perturbed by exposure to chemicals and drugs (Garcia et al., 2005; Brubaker et al., 2009; Creeley et al., 2013) during brain development and adulthood. Therefore, it is essential to develop new human in vitro models that also can capture the function of glial cells and allow the quantification of myelin and the study of its interaction with other CNS cell types in a reproducible way.

2 Materials and Methods

iPSC generation

CDD-1079Sk (ATCC® CRL-2097™), IPS IMR90 (WiCELL) and ATCC-DYP0730 Human (IPS) Cells (ATCC® ACS-1003™) fibroblasts were originally purchased from ATCC. Human iPSCs were generated with the EBV-based vectors as previously described (Wen et al., 2014). All studies followed institutional IRB protocols approved by the Johns Hopkins University School of Medicine. Colonies of iPSCs were manually picked after 3-6 weeks for further expansion and characterization. iPSCs (passage ≤ 20) were cultured on irradiated MEFs in human embryonic stem cell (hESC) medium comprising D-MEM/F12 (Invitrogen), 20% Knockout Serum Replacement (KSR, Invitrogen), 2 mM L-glutamine (Invitrogen), 100 μM MEM NEAA (Invitrogen), 100 μM β-mercaptoethanol (Invitrogen), and 10 ng/mL human basic FGF (bFGF, PeproTech). Media were changed daily and iPSC lines were passaged using collagenase (Invitrogen, 1 mg/mL in D-MEM/F12 for 1 hr at 37°C). Experiments showed in the main manuscript has been done using C1 iPSC derived cells, however additional experiments with IPS IMR90 and DYP0730 are shown in the supplementary file (Fig. S1 at https://doi.org/10.14573/altex.1609122s1).

Neuronal Progenitor Cells (NPC) production

NPC generation followed the previous published protocol (Wen et al., 2014). After NPC generation, iPSCs colonies were detached and NPC colonies were expanded in poly-l-ornithine and laminin-coated 175 mm flask in StemPro® NSC SFM (Life Technologies). Half of the media was changed every day. Cultures were maintained at 37°C in an atmosphere of 5% CO₂.

BMPS differentiation

At 100% confluence NPCs were detached mechanically (by scraping) and counted. 2x10⁵ cells per well were plated in 2 mL of medium in non-treated 6 well-plates. Cells were grown in NPC media for two days under constant gyration shaking (88 rpm) allowing aggregation by using a CO₂ resistant plate shaker. Subsequently, medium was changed to differentiation medium (Neurobasal® electro Medium (Gibco) supplemented with 5% B-27® Electrophysiology (Gibco), 1% glutamax (Gibco), 0.02 μg/ml human recombinant GDNF (Gemini), 0.02 μg/ml human recombinant BDNF (Gemini)). Cultures were maintained at 37°C, 5% CO₂ under constant gyration shaking (88 rpm) for up to eight weeks. Differentiation medium was routinely changed every two days.

Size measurement

Aggregates (n=20) from three independent experiments were randomly selected per time point for obtaining pictures and measuring size using SPOT software 5.0. Results are expressed as mean ± SD (Fig. 1C). Cells were kept two days in NPC medium, indicated as NPC med. 2d on Fig. 1C.

RNA and miRNA extraction

Total RNA was extracted from aggregates every week up to eight weeks of differentiation using Tripure (Roche) according to Chomczynski and Sacchi (Chomczynski and Sacchi, 1987). RNA quantity and purity was determined using NanoDrop 2000c (Thermo Scientific). One microgram of RNA was reverse-transcribed using the M-MLV Promega Reverse Transcriptase (Promega) according to the manufacturer’s recommendations. For miRNA reverse-transcription 60 ng of RNA were reverse transcribed using TaqMan microRNA Reverse transcription kit in combination with miRNA specific stem-loop primers, which are part of TaqMan microRNA expression assay. Up to eight stem-loop primers were multiplexed in one reaction.

Quantitative RT-PCR

The expression of genes was evaluated using specific TaqMan® gene expression assays (Life Technologies). miRNA expression was analyzed using TaqMan microRNA expression assay in combination with TaqMan miRNA Reverse Transcription kit using the protocol described in (Smirnova et al., 2015). Tab. 1 shows a summary of the genes assayed. Real-time RT-PCR was performed using a 7500 Fast Real Time system machine (Applied Biosystems). Fold changes were calculated using the 2(−ΔΔCt) method (Livak and Schmittgen, 2001). β-actin and 18s were used as housekeeping genes for mRNA and RNU44 for miRNA. Data are presented as mean ± SD, normalized to housekeeping genes and week 0.
Tab.1: Gene and miRNAs TaqMan Assays

List of the primers used for the experiments.

<table>
<thead>
<tr>
<th>Assay ID</th>
<th>Assay Type</th>
<th>Catalog Number</th>
<th>Assay Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hs01060665</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>BACT</td>
</tr>
<tr>
<td>Hs99999001</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>18S</td>
</tr>
<tr>
<td>Hs04187831</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>NES</td>
</tr>
<tr>
<td>Hs01052443</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>Ki67</td>
</tr>
<tr>
<td>Hs01088112</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>PAX6</td>
</tr>
<tr>
<td>Hs00909233</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>GFAP</td>
</tr>
<tr>
<td>Hs00300164</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>OLIG2</td>
</tr>
<tr>
<td>Hs00902901</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>S100B</td>
</tr>
<tr>
<td>Hs00609557</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>GRIN1</td>
</tr>
<tr>
<td>Hs00165941</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>TH</td>
</tr>
<tr>
<td>Hs00871228</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>GABRA1</td>
</tr>
<tr>
<td>Hs01056893</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>GAD1</td>
</tr>
<tr>
<td>Hs00199577</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>SYN1</td>
</tr>
<tr>
<td>Hs00232429</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>TBR1</td>
</tr>
<tr>
<td>Hs01003383</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>SNCA</td>
</tr>
<tr>
<td>Hs01003430</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>KEAP1</td>
</tr>
<tr>
<td>Hs00929425</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>NDUFB1</td>
</tr>
<tr>
<td>Hs01101219</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>ATP5C1</td>
</tr>
<tr>
<td>Hs00919163</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>ATP5O</td>
</tr>
<tr>
<td>Hs00354836</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>CASP1</td>
</tr>
<tr>
<td>Hs00263981</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>CNP</td>
</tr>
<tr>
<td>Hs01054576</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>FOXO1</td>
</tr>
<tr>
<td>Hs00188193</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>SLC1A3</td>
</tr>
<tr>
<td>Hs00936217</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>FOXO4</td>
</tr>
<tr>
<td>Hs00892663</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>LMX1A</td>
</tr>
<tr>
<td>Hs00232764</td>
<td>TaqMan® Gene Expression Assay</td>
<td>4331182</td>
<td>FOXA2</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Assay ID</th>
<th>Assay Type</th>
<th>Catalog Number</th>
<th>Assay Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1182</td>
<td>TaqMan® microRNA Assay</td>
<td>4427975</td>
<td>mmu-miR-124a</td>
</tr>
<tr>
<td>2216</td>
<td>TaqMan® microRNA Assay</td>
<td>4427975</td>
<td>hsa-miR-128a</td>
</tr>
<tr>
<td>457</td>
<td>TaqMan® microRNA Assay</td>
<td>4427975</td>
<td>hsa-miR-132</td>
</tr>
<tr>
<td>2247</td>
<td>TaqMan® microRNA Assay</td>
<td>4427975</td>
<td>hsa-miR-133b</td>
</tr>
<tr>
<td>1129</td>
<td>TaqMan® microRNA Assay</td>
<td>4427975</td>
<td>mmu-miR-137</td>
</tr>
<tr>
<td>1094</td>
<td>Control miRNA Assay</td>
<td>4427975</td>
<td>RNU44</td>
</tr>
</tbody>
</table>

Immunocytochemistry of the BMPS

BMPS were fixed in 4% paraformaldehyde, washed three times in PBS and then incubated for one hour in blocking solution (5% normal goat serum (NGS) in PBS with 0.4% TritonX), BMPS were incubated at 4°C for 48 hours with a combination of primary antibodies (Tab. 2) in 3% NGS, 0.1% TritonX in PBS. BMPS were washed in PBS three times and incubated with secondary antibody for one hour in PBS with 3% NGS at room temperature. Double immunostaining was visualized using the proper combination of secondary antibodies (e.g. goat anti-rabbit secondary antibody conjugated with Alexa 594 and goat anti-mouse secondary antibody conjugated with Alexa 488 (Molecular Probes)). Nuclei were counterstained with DRAQ5 dye (Cell Signaling; 1:5000 in 1X PBS) or NucRed Live (Molecular Probes) for 15 minutes, mounted on slides with coverslips and Prolong Gold antifade reagent (Molecular Probes); negative controls were processed omitting the primary antibody. Images were taken using a Zeiss LSM 510 confocal microscope. The experiments were performed in duplicates. 3D reconstruction was done using Imaris 7.6.4 software for scientific imaging.

Tab. 2: Primary antibodies used in the experiments

<table>
<thead>
<tr>
<th>Antibody</th>
<th>Host</th>
<th>Type</th>
<th>Source</th>
<th>Dilution</th>
</tr>
</thead>
<tbody>
<tr>
<td>NF-H</td>
<td>Rabbit</td>
<td>Polyclonal</td>
<td>Enzo</td>
<td>1:1000</td>
</tr>
<tr>
<td>GFAP</td>
<td>Rabbit</td>
<td>Polyclonal</td>
<td>Dako</td>
<td>1:500</td>
</tr>
<tr>
<td>Olig1</td>
<td>Mouse</td>
<td>Monoclonal</td>
<td>Millipore</td>
<td>1:500</td>
</tr>
<tr>
<td>CNPase</td>
<td>Mouse</td>
<td>Monoclonal</td>
<td>Millipore</td>
<td>1:500</td>
</tr>
<tr>
<td>Calbindin</td>
<td>Mouse</td>
<td>Monoclonal</td>
<td>SIGMA</td>
<td>1:500</td>
</tr>
<tr>
<td>NOGO-A</td>
<td>Rabbit</td>
<td>Polyclonal</td>
<td>Santa Cruz</td>
<td>1:500</td>
</tr>
<tr>
<td>Map2</td>
<td>Mouse</td>
<td>Monoclonal</td>
<td>Chemicon</td>
<td>1:1000</td>
</tr>
<tr>
<td>MBP1-SM99</td>
<td>Mouse</td>
<td>Monoclonal</td>
<td>COVANCE</td>
<td>1:1000</td>
</tr>
<tr>
<td>SM-I32</td>
<td>Mouse</td>
<td>Monoclonal</td>
<td>Stenberger Monoclonals</td>
<td>1:2000</td>
</tr>
<tr>
<td>Synaptophysin</td>
<td>Mouse</td>
<td>Monoclonal</td>
<td>SIGMA</td>
<td>1:500</td>
</tr>
<tr>
<td>VGILUT1</td>
<td>Rabbit</td>
<td>Polyclonal</td>
<td>Alpha Diagnostic</td>
<td>1:500</td>
</tr>
<tr>
<td>TH</td>
<td>Mouse</td>
<td>Monoclonal</td>
<td>Millipore</td>
<td>1:250</td>
</tr>
<tr>
<td>Nestin</td>
<td>Rabbit</td>
<td>Polyclonal</td>
<td>Millipore</td>
<td>1:200</td>
</tr>
<tr>
<td>Ki67</td>
<td>Rabbit</td>
<td>Polyclonal</td>
<td>abcam</td>
<td>1:100</td>
</tr>
<tr>
<td>Caspase3</td>
<td>Rabbit</td>
<td>Polyclonal</td>
<td>R&amp;D</td>
<td>0.2µg/ml</td>
</tr>
<tr>
<td>OLIG1</td>
<td>Mouse</td>
<td>Monoclonal</td>
<td>Millipore</td>
<td>1:200</td>
</tr>
<tr>
<td>TUJ1</td>
<td>Mouse</td>
<td>Monoclonal</td>
<td>Stemcell technologies</td>
<td>1:200</td>
</tr>
</tbody>
</table>
Automated quantitation of cell types
BMPS were differentiated for eight weeks. Randomly selected pictures from three experiments were acquired by confocal imaging and then analyzed with a custom algorithm created with the Cellomics TargetActivation (Thermo Fisher Scientific, Pittsburgh, PA) image-analysis software package. With this algorithm, we identified cells based on DRAQ5 stained nucleus and quantified oligodendrocytes and astrocytes based on staining of CNPase, NOGO1 and GFAP.

Myelination assessment and quantification
To calculate the percentage of axonal myelination, we used a semi-automated computer platform, termed computer-assisted evaluation of myelin formation (CEM) (Kerman et al., 2015), which uses NIH Image J built-in tools as well as Math lab processing functions. The results were generated as pixel counts and percent values. The percent of myelinated axons was calculated by dividing the pixel count for myelin by the pixel count for axons after cell body removal and multiplying by 100. For each time point at least 18 fields from at least two independent experiments were analyzed.

Electron microscopy
BMPS aggregates were collected at two, four and eight weeks, respectively, and were fixed in 2% glutaraldehyde and 4% formaldehyde in 0.1M Sodium Cacodylate buffer (EMS, electron microscopy sciences) pH 7.4 with 3% sucrose and 3 mM CaCl2. Post-fixation was done with 2% osmium for 2 hours. The BMPS aggregates were then stained en bloc with 2% uranyl acetate in distilled water for 30 min and subsequently dehydrated in graded ethanol. Embed 812 (EMS) was used as the embedding media. Thin sections (70-80 nm) were cut on a Reichert Jung Ultracut E microtome and placed on formvar-coated 100 mesh copper grids. The grids were stained with uranyl acetate followed by lead citrate and the sections were examined with a Zeiss Libra 120 electron microscope.

Flow cytometry
In order to quantify percentage of NPCs and neurons within the aggregates, flow cytometry for NPC and neuronal markers was performed according to a previously published protocol (Smirnova et al., 2015) with some optimization steps for 3D cultures: Aggregates were washed once with PBS/1mM EDTA and trypsinized directly in the well using TrypLE Express containing 4 units/ml DNAse for 30 min at 37°C on the shaker. Pipetting the aggregates up and down with a 1 ml syringe and a 26G3/8 needle ensured generation of single cell suspension. Cells were counted, washed once with PBS/1 mM EDTA, fixed with 2% PFA for 20 min at 4 °C, washed twice with PBS/1% BSA and blocked for 30 min in blocking solution (PBS/1% BSA/0.15% saponin/10% NGS). 1x10⁶ cells were stained for one hour at 4°C with fluorochrome-conjugated antibodies dissolved in blocking solution (Tab. 3). Unstained cells as well as cells incubated with isotype controls were used as negative controls to set the gates for measurements. Cells were washed twice with PBS/1% BSA/0.15% saponin, and once with PBS/1% BSA. Flow cytometry was performed using a Becton Dickinson FACS Calibur system by measuring 10⁶ gating events per measurement. Data was analyzed using FlowJo v10 software (Tab. S1 at https://doi.org/10.14573/altex.1609122).

Microelectrode array (MEA) recordings
After eight weeks of differentiation, BMPS were plated on 48-well MEA plates (Axion Biosystems) previously coated with Matrigel. During ten days spontaneous electrical activity was recorded using the “Maestro” MEA platform and Axion’s Integrated Studio (AXIS) software (Axion Biosystems). Each well of the 48-well MEA plate contains 16 individual microelectrodes (~40-50 µm diameter, center-to-center spacing 350µm) with integrated ground electrodes, resulting in a total of 768 electrodes/plate. All recordings were performed at a constant temperature of 37°C. Prior to twenty minutes recording the MEA plates were placed in the Maestro MEA platform and equilibrated for 5 min. AXIS software was used to control heating system and to monitor the recordings, which includes simultaneously sampling of the channels at 12.5 kHz/channel with a gain of 1200x and a band pass filter of 200-5000 Hz. After recording the RAW-files were re-recorded with AXIS to convert the data into a spike file, which includes spike timing and profile information. A variable threshold spike detector was used for the spike-file and was set at six times standard deviations of the rms-noise on each channel. The spike file was later used for data analysis with NeuroExplorer® (Nex Technologies) to convert data into Microsoft Excel files. Using the function rate histogram, a summary of the spikes of all electrodes of one plate was put into one Excel sheet. Only electrodes that recorded activity higher than 0.05 spikes/sec at least once over the time measured were included for data analysis.

Statistical analysis
Statistical analyses were performed using GraphPad InStat 3. The Dunnett’s test was applied to all the experiments shown here that compare to a control group. Statistically significant values (p <0.01) are marked with an asterisk (*). For
myelination quantification at the different time points, a Kruskal-Wallis test was employed, statistical significance was considered for p values < 0.05.

3 Results

3.1 Development of a size-controlled BMPS

Different technologies have been used to generate BMPS over the last three years, however, most studies published to date do not allow for controlling the organoid size and shape. The BMPS model established here followed a stepwise differentiation protocol (Fig. 1A). In the final step, cells were differentiated into various neuronal and glial cell types during constant gyratory shaking. This technique induced spherical shapes and controlled the size (below 350 μm) of the BMPS (Fig. 1C), a size that avoids necrosis in the center of the sphere due to nutrient and oxygen deprivation observed in larger spheroids (Fig. 2B c-d). This technique allows producing several batches with different conditions at the same time. Without the shaking condition, aggregates tend to stick together, grow in different shapes, attach to the bottom and in some point get necrotic in the middle of the sphere. Five days after initiation of aggregation in NPC medium, spheres were on average 130 ± 5 μm in diameter. From day 17 onwards size remained constant around 310 μm. Different cell lines are behaving in different ways, and optimization of the speed is required in order to control the shape.

Fig. 1: Characterization of BMPS during differentiation I. (A) Diagram of the differentiation protocol. (B) Co-immunostaining of MAP2+ neurons with the maturation marker Nestin at 2, 4, and 8 weeks showed a progressive increase of MAP2+ neurons and decrease of NES+ cells over time, demonstrating neuronal maturation. (C) Size of aggregates measured during the 3D neuronal differentiation. Negative days on the x-axis represent 3D cells cultured in NPC medium while positive days represent 3D cells cultured in differentiation medium. Inserted phase contrast image shows several aggregates at 15 days of differentiation with an average diameter of 310 μm. (D) BMPS mRNA and miRNA expression of different markers during differentiation (d: right y-axis relative quantification of GRIN1 and GABRA1; MBP, FOXA2, and SLC1A3). (E) Flow cytometry population analysis of BMPS at different stages of differentiation. Scale Bar: 20 μm
3.2 Expression of CNS-specific genes and miRNA during development and differentiation of the BMPS model

In order to characterize different stages of the differentiation and the maturation process, BMPS were collected every week up to eight weeks of differentiation (Fig. 1D, Fig S1A). Analysis of different neuronal and glial cell-specific genes by quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) was performed to characterize the presence of neurons, astrocytes, oligodendrocytes and neural precursor cells (NPCs). Gene expression of the cell proliferation marker Ki67 decreased by 95% after two weeks of differentiation (Fig. 1A). The remaining Ki67 expression is likely due to the presence of a small population of NPCs and other proliferating cell types such as oligodendrocytes and astrocytes (Fig. 1D b). After eight week differentiation, cells showed less than 2% Ki67 positive cells (Fig 3c e). Astrocyte specific genes (S100B and GFAP) showed a constant increase expression after two weeks, while oligodendrocyte genes were observed later, after six weeks of differentiation, as shown by Olig2 gene expression (Fig. 1D b).

Gene expression of specific neurotransmitters or their receptors was used to characterize the identity of different neuronal populations (Fig. 1D). GRIN1, which encodes the essential Glutamate [NMDA] receptor subunit zeta-1 (Monyer et al., 1992), was increased at very early stages of differentiation (one week after induction of differentiation) and continued to increase up to five weeks (Fig. 1D). Similarly, Glutamate decarboxylase 1 (GAD1), a GABAergic neuronal gene marker, showed increased expression during the first four weeks of differentiation, reaching a plateau thereafter. GABRA1, which encodes the gamma-aminobutyric acid (GABA) receptor showed a steady increase of expression after two weeks and reached its maximal increase of a 150-fold change at eight weeks compared to week 0 (Fig. 1D). The expression of tyrosine hydroxylase (TH) a gene, that identifies dopaminergic neurons, was observed first after three weeks, showing delayed differentiation compared to glutamatergic neurons. Moreover other markers for specific part of the brain, such as ventral midbrain neuron marker LMX1A, FOX1 and FOX2 (Hedlund et al., 2016; Stott et al., 2013), cerebral cortex marker FOX04, or markers for myelination CNP and MBP (Li and Richardson, 2008; Agrawal et al., 1994) and L-glutamate transport SLC1A6 (Sery et al., 2015) has been studied (Fig. 1D d).

MicroRNAs (miRNA), known as posttranscriptional regulators of developmental timing, have been established as markers for study of the neural differentiation process (Li and Jin, 2010) and were used here to characterize the BMPS. mir-124, the most abundant brain miRNA, was strongly expressed in the earlier stages of differentiation, then slightly down-regulated at eight weeks of differentiation. This finding correlates with previous studies, where mir-124 was shown to promote neuronal lineage commitment at early stages of neural stem cells specification by targeting anti-neuronal factors (Li and Jin, 2010). mir-128, a modulator of late neural differentiation, was strongly up-regulated after five weeks of differentiation. mir-137, the most induced miRNA over time in our system, is known as a regulator of neural differentiation in embryonic stem cells (ESCs) (Tarantino et al., 2010), mir-132 and mir-133b, which are involved in regulation of dopaminergic neuron maturation and function, were induced at week three of differentiation, a finding, that correlates with the gene expression pattern of TH (Fig. 1D d). These results support the view of a coordinated mechanism of neuronal differentiation as reflected by the patterns of neuronal gene and miRNA expression and neuronal neurotransmitter identity.

3.3 Characterization by flow cytometry analysis shows neuronal maturation of the human iPSC derived BMPS over time

In order to quantify cell populations in the iPSC-derived BMPS and verify the reproducibility between experiments and batches of the cell line (C1, CRL-2097), flow cytometry was performed at different stages of differentiation using CNS-specific antibodies (Tab. 1). Flow cytometry allowed quantifying 60% of cells with proliferation marker (Ki67) at the NPCs stage (week 0), which was reduced during differentiation down to 9% at two weeks, 7% at four weeks and 1% at eight weeks (Fig. 1E, 3C e). This confirms the gene expression data and indicates a fast reduction of proliferating cells after induction of differentiation. The number of SOX1-, SOX2- and NES-positive (NPC marker) cells in the NPC population (week 0) was 46%, 68% and 60%, respectively. SOX1, SOX2 and NES expression was reduced dramatically with differentiation, showing very low positive populations at eight weeks (2%, 3% and 2%, respectively). The reduction in the NPC cell population during differentiation was corroborated by the measurement of Doublecortin (DCX), a microtubule-associated protein expressed in neuroblasts and immature neurons: The number of DCX-positive cells in NPC (week 0) was around 30%, which reduced to 2% at two, 17% at four and 4% at eight weeks, respectively. The marker for mature neurons, Tuj1 (neuron-specific class III beta-tubulin) presented the opposite pattern. Analysis showed low levels of Tuj1-positive cells at the NPC stage (week 0) with increase for up to 70% of positive cells after two weeks of differentiation that remained constant until eight weeks, which is in agreement with existing data published by Pasca and collaborators (Pasca et al., 2015).

Quantification of the cell population in at least three independent experiments showed low variability between cultures, demonstrating the reproducibility of the system. The variation (standard deviation, SD) between experiments decreased with the cell differentiation process and was very small at the latest maturation stage (eight weeks); DCX SD 0.9 %, Ki67 SD 0.2 %, SOX1 SD 0.7 %, SOX2 SD 1.2 %, NES SD 0.7 % and Tuj1 SD 9.8 % (Fig. 1E). These results indicate that after eight weeks of differentiation the cellular composition is similar and shows high reproducibility between different BMPS experiments.

3.4 Immunohistochemistry and electron microscopy reveal a variety of differentiated and mature cell types in the BMPS, including functional oligodendrocytes

In order to further assess the cellular composition and the maturation of the cells within the human BMPS, immunohistochemistry and electron microscopy techniques were employed. We observed different neuronal subtypes in the BMPS including dopaminergic (TH-positive neurons), glutamatergic (VGLUT1-positive neurons) and GABAergic interneurons (CALBINDIN-positive neurons) (Fig. 3A). Moreover, the BMPS matured over time of differentiation as seen
by decreased Nestin-positive cells (Fig. 1B) and increased cell-cell interactions (neuron-neuron and neuron-glia) as subsets of neurons showed several processes, resembling dendritic and axonal projections (Fig. 3A, Video at https://doi.org/10.14573/altex.1609122s2).

Fig. 2: Characterization of BMPS during differentiation II. (A) Comparison of expression of neuronal and glial markers at 2 and 8 weeks. At 2 weeks, oligodendrocytes (O1, CNPase and NOGOA) were identified without a preferential localization (a, b, e, f, i, j), later they resemble human oligodendrocytes and localize in close proximity with axons (c, d, g, h, k, l). At 2 weeks there are few MAP2-positive cells without identifiable neuronal shape (i, j) whereas at 8 weeks the MAP2+ cells acquire a well-defined dendritic network (k, l). The number of astrocytes and density of the astroglial network increased with time of differentiation (GFAP) (g, h). (B) Co-immunostaining of neurons (MAP2) with cell-division marker KI67 showed that some cells are dividing at 8 weeks (a, b). There was also a small degree of apoptosis demonstrated by positive staining with CASP3 at 8 weeks (c). CASP 3-positive nuclei did not co-localize with mature neurons (d). (C) Ultrastructure analysis by electron microscopy at 8 weeks BMPS showed evidence of cell-to-cell junctions demonstrating functional interactions between the cells (arrows, a, b). Nuclear variation was confirmed by the presence of a few apoptotic nuclei (c) and normal healthy nuclei (d). NF: Neurofilament-heavy-chain, MAP2: Microtubule-associated-protein 2, GFAP: Glial-fibrillary-acidic protein, O1: Olig1, CNPase: 2',3'-Cyclic-nucleotide-3'-phosphodiesterase. CASP3: Caspase3.
Fig. 3: Morphologic characterization of mature human BMPS. (A) At 8 weeks, neuronal populations exhibited a diversity of neurotransmitter identities as shown by identification of dopaminergic TH⁺ (a, b), glutamatergic VGLUT1⁺ (c, d) and GABAergic calbindin⁺ (e, f) neurons. Neurons disclosed characteristic axons (NF) and synaptic proteins (SYN) (g, h). (B) Two distinctive glial populations were identified in close interaction with neuronal populations, GFAP⁺ astroglia and CNPase⁺, O1⁺, NOGOA⁺ oligodendroglia. O1⁺ oligodendrocytes were closely associated with axonal processes (NF) (a, b), CNPase⁺ oligodendroglia appeared mixed among GFAP⁺ astroglia (c, d) and exhibited the characteristic multipolar glial processes, which extended from the perykaria (e, f). NOGOA⁺ cells were associated with MAP⁺ neurons (g, h). (C) Example of custom algorithm created using the Cellomics Target Activation image-analysis software package to study astrocytes and oligodendrocytes (a, b, c, d). Quantification of cell populations as a percentage of the total nuclei count of GFAP, Calbinding, CNPase, NOGOA, Olig1, Ki67 and Caspase positive cells at 8 weeks (e). (D) Co-expression of mature oligodendroglia markers (MBP and O2). (E) Expression of neuronal markers (VGLUT, TUJ1, SYN).

A subset of neuroglial cells exhibited immunoreactivity for markers such as NOGOA, O1, O2 and CNPase (Fig. 2A a-l, Fig. 3B a-j, Fig. 2D, Fig. S1A), which identifies the presence of mature oligodendrocytes in the BMPS (Deng and Poretz, 2003; Schwab, 2010). Automatic image quantification showed that oligodendrocytes (CNPase, NOGOA and Olig1) comprised 3, 9 and 11% of the total cell population, respectively, at eight weeks of differentiation (Fig. 3C e). Similar to the in vivo physiology, these cells were immunoreactive for myelin basic protein (MBP) (Fig. 4), which characterizes myelinating oligodendrocytes (Fancy et al., 2011). Moreover, they had morphological features of normal human oligodendrocytes in vivo and appeared in close contact with neuronal processes (Fig 2A, Fig. 3 a-b, Fig. 4).

This pattern of immunostaining suggests that oligodendrocytes within the BMPS are functional and myelinate axons. MBP expression increased with time of differentiation (Fig. 4A). Morphometric studies of neuronal processes identified by immunostaining with NF antibodies and MBP markers were used to estimate the percentage of myelinated
axons within the BMPS (Kerman et al., 2015) with an average of 4% at two weeks, 25% at four weeks and 42% at eight weeks of differentiation (p < 0.001) (Fig. 4C). All analyzed BMPS showed similar extent of myelination at the same differentiation window. Percentages have been calculated as the mean of at least 18 microscopy fields from at least 3 individual BMPS in 2 different experiments. Ultrastructural analysis by electron microscopy demonstrated oligodendrocyte cell projections that enwrapped cell processes resembling axons after eight weeks of differentiation (Fig. 4D b).

GFAP-positive cells formed numerous cell processes organized in a network typical for human astrocytic processes in vivo, with established contacts to other glial cells and neurons (Fig. 3B c, d, e, f and Fig. 2A). Imaging quantification revealed 19% of astrocytes in the total population (Fig. 3C). Altogether, cell morphology, immunostaining and cell-cell interactions shown by neuronal and glial cell populations demonstrates that the BMPS recapitulates cellular types and patterns of interactions seen in the human CNS and can therefore be considered organotypic. The micropysiological system published by Pasca et al. has shown similar quantity of GFAP-positive cells but at later stages of differentiation (Pasca et al., 2015).

The morphology of cell nuclei observed by immunocytochemistry and electron microscopy showed some variations attributed to (i) cell proliferation as seen by positive staining for Klf67 and NES markers and (ii) nuclear fragmentation likely associated with apoptosis as indicated by CASPASE-3 staining (Fig. 2B and 2C). This variation likely reflects the active stages of cell differentiation that BMPS exhibit during development (Meijer et al., 2012). Importantly, Caspase 3-positive nuclei did not concentrate in the center of the spheres (Fig. 2B) and thus do not appear linked to deprivation of oxygen or nutrients. Caspase has been quantified at eight weeks in BMPS (Fig. 3C e).

Fig. 4: Myelination in BMPS. (A) Co-immunostaining of neurons (NF) and the myelin marker MBP at 2, 4, and 8 weeks of differentiation (a, b, c, respectively) showed progressive increase of MBP+ cells in association with axonal processes. (B) 3D-reconstruction based on confocal z-stacks at 8 weeks demonstrating a “wrapping” myelinating process, which resembled the myelination of axons in human CNS. (C) MBP+ oligodendrocytes (green) issued processes in close association with axons (red) and seemed to enwrap them at 8 weeks (a, b, c). Myelination calculated as the mean percentage MBP positive oligodendrocyte processes coverage of NF-positive axons (a, b, c) at 2, 4 and 8 weeks in at least two independent experiments showed significant increase of myelination observed with time of differentiation (p < 0.001) (d). (D) Electron microscopy analysis of BMPS at 4 and 8 weeks of differentiation identified morphology of axonal structures and cells, which appeared to be myelinating-like processes, which closely resembled cross-sections of myelinated axons of the CNS, were identified at 8 weeks of differentiation (b).

3.5 The BMPS model exhibits neuronal functionality revealed by spontaneous electrical activity

To test the neuronal physiological properties of the cells within the BMPS model, spontaneous electrical activity in BMPS was analyzed by multi-electrode array (MEA) (Fig. 5D). Spontaneous electrical activity was measured from one week after plating up to two weeks. The activity was recorded for 20 minutes at seven different days. Electrodes were considered active when the recorded activity was above 0.05 spikes/sec. Fig. 5A shows a representative heat-map of a 48-well MEA plate from one 20-minute recording. The heat map represents the spike amplitude (μV) with a minimum of 0 μV and maximum of 40 μV (Fig. 5A). The spikes showed a common waveform between different electrodes and measurements (Fig. 5B) and
neurons were repeatedly firing (Fig. 5B). 25 electrodes, distributed over 19 wells, were included after the first step of data analysis. 20 to 40% of these 25 electrodes reached the threshold of 0.05 spikes/sec during each recording. Fig. 5F shows the spike events of active electrodes from one representative 20-minute recording. These data show the potential use of MEA for measuring electrical activity of the 3D BMPS. However, further optimization of the protocol is needed to increase the measurement of the neuronal activity on the electrodes.

Figure 5. Electrical activity as a neuronal function of the BMPS. Cells were cultured in 3D for 8 weeks and then cultured in 48-well MEA plates for 4 more weeks. (A) Heat map recordings from a 48-well plate. Illustration of an active well showing (B) spike morphology and (C) spike activity. (D and E) Phase-contrast imaging of the mini-brains on MEAs, electrode diameter is 40-50 µm and inter-electrode space is 350 µm. (F) Activity pattern recordings over 0.05 spikes/sec of the electrode over 10 min.

4 Discussion

The human BMPS model is a versatile tool for more complex testing platforms as well as for research into CNS physiology, mechanisms associated with (developmental) neurotoxicity and pathogenesis of neurological disorders. Stem cell-derived brain model systems developed in the past few years have shown the capability to recapitulate some of the in vivo biological processes (Juraver-Geslin and Durand, 2015; Nakano et al., 2012; Krug et al., 2014) and have an advantage over other classical in vitro models as they facilitate the study of various differentiation mechanisms, developmental processes and diseases (Lancaster et al., 2013). Combining stem cells with emerging culturing techniques such as 3D culture (Alépée et al., 2014; Hartung, 2014) promotes the development of new more complex human in vitro models, such as microphysiological systems (Andersen et al., 2014; Marx et al., 2016), that enhance modeling of the in vivo brain (Pasca et al., 2015; Lancaster et al., 2013). However, they often require complicated protocols that may reduce the reproducibility of the system and make it difficult to use in other fields such as chemical toxicity and drug screening. Some of these complex organoids models are also limited by large diameters, which can lead to extensive cell death in the middle due to insufficient diffusion of oxygen and nutrients (Lancaster et al., 2013) and other artifacts. Recently, attempts to generate more reproducible brain microphysiological systems were published using rat primary cortical tissue (Dingle et al., 2015). In this study, we have developed a human in vitro model by the gyratory shaking technique that enables reliably generation of a high number (about 500 per six-well plate) of viable BMPS that are homogeneous in size and shape. Control of size allowed us to keep
cell aggregates below 350 μM in diameter (Fig. 1C) and avoid disparate morphology and/or necrosis in the center of the spheres. Moreover, the BMPS showed reproducible cell composition by immunomorphological quantification, assessment of imaging-based endpoints and flow cytometry analysis.

The 3D differentiation protocol for the BMPS covers stages from neuronal precursors to different cell types of the mature CNS. At two weeks, BMPS consisted of an immature population of cells, showing minimal neuronal networks, a low percentage of mature astrocytes and oligodendrocytes, and minimal but early stages of myelin basic protein (MBP) expression (Fig. 1D and Fig. 2A). iPSC differentiation into mature BMPS was indicated by decreasing NES expression over time and a progressive expression of mature neuronal and glial markers such as MAP2, GFAP, O1 and MBP. Gene expression studies, flow cytometry, image analysis, immunostaining and miRNA studies have shown increase of cell maturation markers, which follow the BMPS differentiation (Fig. 1, 2, 3 and 4). The presence of GABAergic neurons, dopaminergic neurons and glutamatergic neurons was documented by immunohistochemistry and real-time PCR data (Fig. 1D, Fig. 3A and 3E). Moreover, the BMPS showed spontaneous electrical activity (Fig. 5), indicating neuronal functionality of the system.

Most of the recent BMPS published are entirely focused on neurons and not glial populations (Park et al., 2015; Dolle et al., 2014). Since astrocytes and oligodendrocytes play important roles during neuronal development, plasticity and injury, the presence of glial cell populations in this BMPS model provides an excellent opportunity for the evaluation of neuronal-glial interactions and the role of glia in pathogenesis and toxicity processes. Astrocytes have an important role in protecting neurons, increasing neuronal viability and mitochondrial biogenesis from both exogenous (e.g. chemicals) and endogenous toxicity (Shinozaki et al., 2014; Aguirre-Rueda et al., 2015), especially against oxidative stress (Shao et al., 1997; Schwab and McGeer, 2008). Thus, their presence in a biological system to study disease and neurotoxicity is crucial. Immunohistochemistry and RT-PCR results showed increasing numbers of astrocytes (GFAP-positive cells) in the BMPS model (Fig. 2A, Fig. 1D, 3B) reaching 19% astrocytes of the total cell population at day 8 (Fig. 5, 3C), which is earlier than in previously described cortical spheroids, where similar proportions of GFAP-positive cells were observed first at day 81, at day 86 the number of GFAP+ cells was below 10% (Pascas et al., 2015). We acknowledge that there is a subset of the GFAP+ cells that could still be radial glia as there is some nestin expression even after 8 weeks of development (Lyck et al., 2008; DeAzevedo et al., 2003).

The most novel element of this BMPS is the presence of mature human oligodendrocytes with myelination properties. Immunocytochemical and ultrastructural studies confirmed the morphological identity of these cells (Fig. 4D) as multiple markers for mature oligodendrocytes were expressed by rounded cells with branching processes and membrane sheaths that are similar to the ones found in humans in vivo. The structure and morphology was further confirmed by electron microscopy. Quantitative assessment of the myelination process of MBP immunostaining along axons showed an increase over time of differentiation reaching 42% of myelinated axons at eight weeks (Fig. 4C). 3D reconstruction of confocal z-stacks images (Fig. 4B) and electron microscopy confirmed the wrapping of axonal structures after eight weeks of differentiation (Fig. 4D). These findings are of particular relevance since myelin is a critical element for proper neuronal function and development, and the covering of axons by myelin allows faster action potential transmission, reduces axonal energy consumption and protects the axons from degeneration (Nave, 2010). Furthermore, recent evidence suggests that oligodendrocytes and myelin have a role in the metabolic support of axons independent of their role in action potential conduction, highlighting their importance in neuronal survival (Saab et al., 2013). Very few in vitro models have been developed that can capture the myelination process and most of them are derived from rodent primary cells (Lariosa-Willingham et al., 2016; Schott et al., 2016; Bourre et al., 1979). Some recent studies demonstrate human myelinating oligodendrocytes derived from iPSC (Uemura et al., 2014; Wang et al., 2013), however, only by introducing the cells into mice. To our knowledge, this is the first time that a 3D human microphysiological system, consisting of different types of neurons and glial cells, has achieved such a high percentage of myelination. The ability to assess oligodendroglia function and mechanisms associated with myelination in this BMPS model provides an excellent tool for future studies of neurological disorders such as multiple sclerosis and other demyelinating disorders. As an illustration it was recently discovered that astroglia cells could promote oligodendrogenesis via secreted molecules (Jiang et al., 2016). A human BMPS that consist of neurons, astrocytes and oligodendrocytes is essential to evaluate this mechanism further and to develop a potential therapy for demyelinating disorders.

In conclusion, the BMPS showed here replicates crucial aspects of brain physiology and functionality. The potential for studying developmental and neurodegenerative disorders, brain infections, toxicity and trauma with such a system is growing. Furthermore, the potential to use iPSCs from different donors adds a personalized component to these studies. The high reproducibility and relatively simple protocol, enables future medium-throughput (96-well format) testing of chemicals, drugs and their potential to induce or treat diseases.

References
Andersen, M. E., Betts, K., Dragán, Y. et al. (2014). Developing microphysiological systems for use as regulatory tools—challenges and opportunities. ALTEx 31, 364-367. https://doi.org/10.14573/altex1405151


Hartung, T. (2007). Food for thought... on cell culture. ALTEX 24, 143-152.


Nave, K. A. (2010). Myelination and support of axonal integrity by glia. Nature 468, 244-252. https://doi.org/10.1038/nature09614


Acknowledgement
This work was supported by NIH NCATS (grant U18TR000547 “A 3D Model of Human Brain Development for Studying Gene/Environment Interactions”, PI Hartung) and Alternatives Research & Development Foundation (“A 3D in vitro “mini-brain” model to study Parkinson’s disease”, PI Hartung). The neuroimmunopathology portion of this research was supported by he Bart McLean Fund for Neuroimmunology Research/Project Restore (PB and CAP). We are most grateful for discussions and advice from Dr. Ha Nam Nguyen, Johns Hopkins Medicine, and Dr. Kristen L Willis, Edgewood Chemical Biological Center, Aberdeen, MD. We are grateful for additional financial support by Dorothy Frankel.

Competing financial interests

A provisional patent has been filed by Johns Hopkins University for some of the technologies described in this paper (inventors David Pamies, Helena Hogberg and Thomas Hartung), which was licensed to Organome, LLC. Thomas Hartung is cofounder of Organome LLC. David Pamies and Lena Smirnova consult Organome.

**Correspondence address**
Thomas Hartung, MD PhD  
Center for Alternatives to Animal Testing  
Johns Hopkins Bloomberg School of Public Health  
615 N. Wolfe Str.  
Baltimore, MD, 21205, USA  
e-mail: thartun1@jhu.edu